Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: Evaluation by intravascular ultrasound) extension trial

Atsushi Hirohata, Keizo Yamamoto, Toru Miyoshi, Kunihiko Hatanaka, Satoshi Hirohata, Hitoshi Yamawaki, Issei Komatsubara, Eiki Hirose, Yuhei Kobayashi, Keisuke Ohkawa, Minako Ohara, Hiroya Takafuji, Fumihiko Sano, Yuko Toyama, Shozo Kusachi, Tohru Ohe, Hiroshi Itoh

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: The previous OLIVUS trial reported a positive role in achieving a lower rate of coronary atheroma progression through the administration of Olmesartan, an angiotension-II receptor blocking agent (ARB), for stable angina pectoris (SAP) patients requiring percutaneous coronary intervention (PCI). However, the benefits between ARB administration on long-term clinical outcomes and serial atheroma changes by IVUS remain unclear. Thus, we examined the 4-year clinical outcomes from OLIVUS according to treatment strategy with Olmesartan. Methods: Serial volumetric IVUS examinations (baseline and 14 months) were performed in 247 patients with hypertension and SAP. When these patients underwent PCI for culprit lesions, IVUS was performed in their non-culprit vessels. Patients were randomly assigned to receive 20-40. mg of Olmesartan or control, and treated with a combination of β-blockers, calcium channel blockers, glycemic control agents and/or statins per physician's guidance. Four-year clinical outcomes and annual progression rate of atherosclerosis, assessed by serial IVUS, were compared with major adverse cardio- and cerebrovascular events (MACCE). Results: Cumulative event-free survival was significantly higher in the Olmesartan group than in the control group (p= 0.04; log-rank test). By adjusting for validated prognosticators, Olmesartan administration was identified as a good predictor of MACCE (p= 0.041). On the other hand, patients with adverse events (n= 31) had larger annual atheroma progression than the rest of the population (23.8% vs. 2.1%, p<0.001). Conclusions: Olmesartan therapy appears to confer improved long-term clinical outcomes. Atheroma volume changes, assessed by IVUS, seem to be a reliable surrogate for future major adverse cardio- and cerebrovascular events in this study cohort.

Original languageEnglish
Pages (from-to)134-138
Number of pages5
JournalAtherosclerosis
Volume220
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Coronary Artery Disease
Atherosclerotic Plaques
Stable Angina
Percutaneous Coronary Intervention
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Calcium Channel Blockers
Disease-Free Survival
olmesartan
Atherosclerosis
Cohort Studies
Hypertension
Physicians
Control Groups
Therapeutics
Population

Keywords

  • Angiotensin
  • Arteriosclerosis
  • Atherosclerosis
  • Prevention
  • Ultrasonics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis : Evaluation by intravascular ultrasound) extension trial. / Hirohata, Atsushi; Yamamoto, Keizo; Miyoshi, Toru; Hatanaka, Kunihiko; Hirohata, Satoshi; Yamawaki, Hitoshi; Komatsubara, Issei; Hirose, Eiki; Kobayashi, Yuhei; Ohkawa, Keisuke; Ohara, Minako; Takafuji, Hiroya; Sano, Fumihiko; Toyama, Yuko; Kusachi, Shozo; Ohe, Tohru; Itoh, Hiroshi.

In: Atherosclerosis, Vol. 220, No. 1, 01.2012, p. 134-138.

Research output: Contribution to journalArticle

Hirohata, A, Yamamoto, K, Miyoshi, T, Hatanaka, K, Hirohata, S, Yamawaki, H, Komatsubara, I, Hirose, E, Kobayashi, Y, Ohkawa, K, Ohara, M, Takafuji, H, Sano, F, Toyama, Y, Kusachi, S, Ohe, T & Itoh, H 2012, 'Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: Evaluation by intravascular ultrasound) extension trial', Atherosclerosis, vol. 220, no. 1, pp. 134-138. https://doi.org/10.1016/j.atherosclerosis.2011.10.013
Hirohata, Atsushi ; Yamamoto, Keizo ; Miyoshi, Toru ; Hatanaka, Kunihiko ; Hirohata, Satoshi ; Yamawaki, Hitoshi ; Komatsubara, Issei ; Hirose, Eiki ; Kobayashi, Yuhei ; Ohkawa, Keisuke ; Ohara, Minako ; Takafuji, Hiroya ; Sano, Fumihiko ; Toyama, Yuko ; Kusachi, Shozo ; Ohe, Tohru ; Itoh, Hiroshi. / Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis : Evaluation by intravascular ultrasound) extension trial. In: Atherosclerosis. 2012 ; Vol. 220, No. 1. pp. 134-138.
@article{4d99c034eadf4346b605624556bd9ee3,
title = "Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: Evaluation by intravascular ultrasound) extension trial",
abstract = "Background: The previous OLIVUS trial reported a positive role in achieving a lower rate of coronary atheroma progression through the administration of Olmesartan, an angiotension-II receptor blocking agent (ARB), for stable angina pectoris (SAP) patients requiring percutaneous coronary intervention (PCI). However, the benefits between ARB administration on long-term clinical outcomes and serial atheroma changes by IVUS remain unclear. Thus, we examined the 4-year clinical outcomes from OLIVUS according to treatment strategy with Olmesartan. Methods: Serial volumetric IVUS examinations (baseline and 14 months) were performed in 247 patients with hypertension and SAP. When these patients underwent PCI for culprit lesions, IVUS was performed in their non-culprit vessels. Patients were randomly assigned to receive 20-40. mg of Olmesartan or control, and treated with a combination of β-blockers, calcium channel blockers, glycemic control agents and/or statins per physician's guidance. Four-year clinical outcomes and annual progression rate of atherosclerosis, assessed by serial IVUS, were compared with major adverse cardio- and cerebrovascular events (MACCE). Results: Cumulative event-free survival was significantly higher in the Olmesartan group than in the control group (p= 0.04; log-rank test). By adjusting for validated prognosticators, Olmesartan administration was identified as a good predictor of MACCE (p= 0.041). On the other hand, patients with adverse events (n= 31) had larger annual atheroma progression than the rest of the population (23.8{\%} vs. 2.1{\%}, p<0.001). Conclusions: Olmesartan therapy appears to confer improved long-term clinical outcomes. Atheroma volume changes, assessed by IVUS, seem to be a reliable surrogate for future major adverse cardio- and cerebrovascular events in this study cohort.",
keywords = "Angiotensin, Arteriosclerosis, Atherosclerosis, Prevention, Ultrasonics",
author = "Atsushi Hirohata and Keizo Yamamoto and Toru Miyoshi and Kunihiko Hatanaka and Satoshi Hirohata and Hitoshi Yamawaki and Issei Komatsubara and Eiki Hirose and Yuhei Kobayashi and Keisuke Ohkawa and Minako Ohara and Hiroya Takafuji and Fumihiko Sano and Yuko Toyama and Shozo Kusachi and Tohru Ohe and Hiroshi Itoh",
year = "2012",
month = "1",
doi = "10.1016/j.atherosclerosis.2011.10.013",
language = "English",
volume = "220",
pages = "134--138",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis

T2 - Evaluation by intravascular ultrasound) extension trial

AU - Hirohata, Atsushi

AU - Yamamoto, Keizo

AU - Miyoshi, Toru

AU - Hatanaka, Kunihiko

AU - Hirohata, Satoshi

AU - Yamawaki, Hitoshi

AU - Komatsubara, Issei

AU - Hirose, Eiki

AU - Kobayashi, Yuhei

AU - Ohkawa, Keisuke

AU - Ohara, Minako

AU - Takafuji, Hiroya

AU - Sano, Fumihiko

AU - Toyama, Yuko

AU - Kusachi, Shozo

AU - Ohe, Tohru

AU - Itoh, Hiroshi

PY - 2012/1

Y1 - 2012/1

N2 - Background: The previous OLIVUS trial reported a positive role in achieving a lower rate of coronary atheroma progression through the administration of Olmesartan, an angiotension-II receptor blocking agent (ARB), for stable angina pectoris (SAP) patients requiring percutaneous coronary intervention (PCI). However, the benefits between ARB administration on long-term clinical outcomes and serial atheroma changes by IVUS remain unclear. Thus, we examined the 4-year clinical outcomes from OLIVUS according to treatment strategy with Olmesartan. Methods: Serial volumetric IVUS examinations (baseline and 14 months) were performed in 247 patients with hypertension and SAP. When these patients underwent PCI for culprit lesions, IVUS was performed in their non-culprit vessels. Patients were randomly assigned to receive 20-40. mg of Olmesartan or control, and treated with a combination of β-blockers, calcium channel blockers, glycemic control agents and/or statins per physician's guidance. Four-year clinical outcomes and annual progression rate of atherosclerosis, assessed by serial IVUS, were compared with major adverse cardio- and cerebrovascular events (MACCE). Results: Cumulative event-free survival was significantly higher in the Olmesartan group than in the control group (p= 0.04; log-rank test). By adjusting for validated prognosticators, Olmesartan administration was identified as a good predictor of MACCE (p= 0.041). On the other hand, patients with adverse events (n= 31) had larger annual atheroma progression than the rest of the population (23.8% vs. 2.1%, p<0.001). Conclusions: Olmesartan therapy appears to confer improved long-term clinical outcomes. Atheroma volume changes, assessed by IVUS, seem to be a reliable surrogate for future major adverse cardio- and cerebrovascular events in this study cohort.

AB - Background: The previous OLIVUS trial reported a positive role in achieving a lower rate of coronary atheroma progression through the administration of Olmesartan, an angiotension-II receptor blocking agent (ARB), for stable angina pectoris (SAP) patients requiring percutaneous coronary intervention (PCI). However, the benefits between ARB administration on long-term clinical outcomes and serial atheroma changes by IVUS remain unclear. Thus, we examined the 4-year clinical outcomes from OLIVUS according to treatment strategy with Olmesartan. Methods: Serial volumetric IVUS examinations (baseline and 14 months) were performed in 247 patients with hypertension and SAP. When these patients underwent PCI for culprit lesions, IVUS was performed in their non-culprit vessels. Patients were randomly assigned to receive 20-40. mg of Olmesartan or control, and treated with a combination of β-blockers, calcium channel blockers, glycemic control agents and/or statins per physician's guidance. Four-year clinical outcomes and annual progression rate of atherosclerosis, assessed by serial IVUS, were compared with major adverse cardio- and cerebrovascular events (MACCE). Results: Cumulative event-free survival was significantly higher in the Olmesartan group than in the control group (p= 0.04; log-rank test). By adjusting for validated prognosticators, Olmesartan administration was identified as a good predictor of MACCE (p= 0.041). On the other hand, patients with adverse events (n= 31) had larger annual atheroma progression than the rest of the population (23.8% vs. 2.1%, p<0.001). Conclusions: Olmesartan therapy appears to confer improved long-term clinical outcomes. Atheroma volume changes, assessed by IVUS, seem to be a reliable surrogate for future major adverse cardio- and cerebrovascular events in this study cohort.

KW - Angiotensin

KW - Arteriosclerosis

KW - Atherosclerosis

KW - Prevention

KW - Ultrasonics

UR - http://www.scopus.com/inward/record.url?scp=84155172795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84155172795&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2011.10.013

DO - 10.1016/j.atherosclerosis.2011.10.013

M3 - Article

C2 - 22119063

AN - SCOPUS:84155172795

VL - 220

SP - 134

EP - 138

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -